By Rick Moran
Drugmaker AstraZeneca announced that the vaccine trial they were conducting with Oxford University has been put on hold in order to review safety data following one of the trial patients becoming ill. The company didn’t release any information about what the adverse reaction was, but said the patient was recovering. It’s also possible that the patient’s illness could be unrelated to the vaccine.
This is unusual but not unheard of, and holds are fairly common. With 20,000 participants, there were bound to be a couple of patients who had a reaction to the vaccine.
But the timetable to approve the vaccine may slip.
An individual familiar with the development said researchers had been told the hold was placed on the trial out of “an abundance of caution.” A second individual familiar with the matter, who also spoke on condition of anonymity, said the finding is having an impact on other AstraZeneca vaccine trials underway — as well as on the clinical trials being conducted by other vaccine manufacturers.
Clinical holds are not uncommon, and it’s unclear how long AstraZeneca’s might last. But the progress of the company’s trial — and those of all Covid-19 vaccines in development — are being closely watched given the pressing need for new ways to curb the global pandemic. There are currently nine vaccine candidates in Phase 3 trials. AstraZeneca’s is the first Phase 3 Covid-19 vaccine trial known to have been put on hold.
Other test sites have also placed a hold on the trials.
